ArticleBMC infectious diseases2019
Clostridium difficile isolated from faecal samples in patients with ulcerative colitis.
Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Two-Dimensional PCR for Simultaneous Detection of Fecal Bacterial Markers in the Diagnosis and Management of Inflammatory Bowel Disease.Journal of inflammation research · 2026Article
- The hidden piece in inflammatory bowel diseases: The significance of intestinal mucus in mediating the bacteria-cells crosstalk.Materials today. Bio · 2025Review
- The analysis of the epidemic status and risk factors associated with different genotypes Clostridioides difficile mixed infection.BMC microbiology · 2025Article
- A new approach for microbe-disease association prediction: incorporating representation learning of latent relationships.BMC medical informatics and decision making · 2025Article
- Global Patterns ofCrohn's & colitis 360 · 2025Article
- Intestinal Microbiome Changes and Clinical Outcomes of Patients with Ulcerative Colitis after Fecal Microbiota Transplantation.Journal of clinical medicine · 2023Article
- Polysaccharide fromNutrients · 2023Article
- Therapy Used to Promote Disease Remission Targeting Gut Dysbiosis, in UC Patients with Active Disease.Journal of clinical medicine · 2022Review
- Molecular epidemiology and clinical characteristics of Clostridioides difficile infection in patients with inflammatory bowel disease from a teaching hospital.Journal of clinical laboratory analysis · 2022Article
- Molecular detection of pathogenic bacteria in the colonic biopsies from patients with Ulcerative Colitis.African health sciences · 2022Article
- The effect of a hydrolyzed protein diet on the fecal microbiota in cats with chronic enteropathy.Scientific reports · 2022Article
- Drug Targeting of Inflammatory Bowel Diseases by Biomolecules.Nanomaterials (Basel, Switzerland) · 2021Review
- What the dental practitioner needs to know about pharmaco-therapeutic modalities of COVID-19 treatment: A review.Journal of dental sciences · 2021Review
- Blastocystis and Clostridioides difficile: Evidence for a Synergistic Role in Colonization Among IBD Patients with Emphasis on Ulcerative Colitis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021Article
- Characterization of Gut Microbiota in Hospitalized Patients with Clostridioides difficile Infection.Current microbiology · 2020Article
- COVID-19: Present and Future Challenges for Dental Practice.International journal of environmental research and public health · 2020Review
- Clostridium Difficile Infection in Patients Impact Suspected Cytomegalovirus Infection in Patients with Inflammatory Bowel Disease.Materia socio-medica · 2020Article
- Intestinal Microbiota in Elderly Inpatients withInfection and drug resistance · 2020Article
- Colonization of ToxigenicFrontiers in cellular and infection microbiology · 2020Article
- Phenotypic and Genotypic Characteristics ofInfection and drug resistance · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUlcerative colitis (UC) is an inflammatory bowel disease (IBD) that is widely identified worldwide. This study aimed to investigate the phenotypic characterization and molecular typing of Clostridium difficile isolates among patients with UC at an inflammatory bowel disease clinic in Iran.
methodsIn this cross-sectional study, conducted from April 2015 to December 2015, 85 UC patients were assessed for C.difficile infection (CDI). C. difficile isolates were characterized based on their toxin profile and antimicrobial resistance pattern. Multi-locus sequence typing analysis (MLST) and PCR ribotyping were performed to define the genetic relationships between different lineages of toxigenic strains.
resultsThe prevalence of C. difficile isolates was 31.8% (27/85) in patients, of those 15 patients (17.6%) had CDI. Three different sequence types (STs) identified based on MLST among the toxigenic isolates, that is ST54 (33.3%), ST2 (53.3%), and ST37 (13.6%). C. difficile strains were divided into four different PCR-ribotypes (012, 014, 017 and IR1). The most common ribotype was 014 accounting for 48.3% (7/15) of all strains. The strains isolated during the first episode and recurrence of CDI usually belonged to PCR ribotype 014 (ST2). A high rate of CDI recurrence (14.1%, 12/85) experienced in UC patients. Colonization of the gastrointestinal tract with non-toxigenic C. difficile strains was frequent among patients with mild disease. All C. difficile isolates were susceptible to metronidazole, and vancomycin, 86 and 67% of isolates were resistant to clindamycin and erythromycin respectively. There was no correlation between the toxin type and antibiotic resistance (p > 0.05).
conclusionOverall CDI is rather prevalent in UC patients. All patients with CDI experienced moderate to severe disease and exposed to different antimicrobial and anti-inflammatory agents. Close monitoring and appropriate management including early detection and fast treatment of CDI will improve UC outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.